Molecule
Zavegepant is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults, among other approved uses. It is available as nasal spray. MedsAcross supplies Zavegepant for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
ZAVZPRET is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use ZAVZPRET is not indicated for the preventive treatment of migraine. ZAVZPRET is a calcitonin gene-related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults.
Source: US FDA prescribing information
Zavegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist.
Source: US FDA prescribing information
• The recommended dose is 10 mg given as a single spray in one nostril, as needed. • The maximum dose in a 24-hour period is 10 mg (one spray). • The safety of treating more than 8 migraines in a 30-day period has not been established.
Source: US FDA prescribing information
ZAVZPRET is contraindicated in patients with a history of hypersensitivity reaction to zavegepant or any of the components of ZAVZPRET. Reactions have included anaphylaxis. Patients with a history of hypersensitivity reaction to zavegepant or to any of the components of ZAVZPRET.
Source: US FDA prescribing information
• Hypersensitivity Reactions: If a serious hypersensitivity reaction occurs, discontinue ZAVZPRET and initiate appropriate therapy. Hypersensitivity reactions including anaphylaxis, facial swelling, and urticaria, have occurred with ZAVZPRET. • Hypertension: New-onset or worsening of pre-existing hypertension may occur. • Raynaud’s Phenomenon: New-onset or worsening of pre-existing Raynaud’s phenomenon may occur.
Source: US FDA prescribing information
The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling: • Hypersensitivity Reactions • Hypertension • Raynaud’s Phenomenon Most common adverse reactions (at least 2% of patients treated with ZAVZPRET and greater than placebo) were taste disorders, nausea, nasal discomfort, and vomiting.
Source: US FDA prescribing information
• Avoid use with drugs that inhibit OATP1B3 or NTCP transporters. • Avoid use with drugs that induce OATP1B3 or NTCP transporters. • Avoid use of intranasal decongestants, if unavoidable, administer intranasal decongestants at least 1 hour after ZAVZPRET administration.
Source: US FDA prescribing information
Store ZAVZPRET at controlled room temperature, 20°C to 25°C (68°F to 77°F), with excursions permitted between 15°C to 30°C (59°F to 86°F). Do not freeze.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
1 presentations of Zavegepant, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Zavzpret 10 mg/0.1 mL nasal sprayNasal | Pfizer Laboratories | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 9 March 2023 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 1 presentations of Zavegepant and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Zavegepant, including Zavzpret.
Yes. The US FDA first approved Zavegepant on 9 March 2023, according to Drugs@FDA.
No listed presentation of Zavegepant is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.